These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children. Liu X; Smits A; Wang Y; Renard M; Wead S; Kagan RJ; Healy DP; De Cock P; Allegaert K; Sherwin CMT Ther Drug Monit; 2019 Feb; 41(1):44-52. PubMed ID: 30299427 [TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy. Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795 [TBL] [Abstract][Full Text] [Related]
5. Optimizing Amikacin Dosage in Pediatrics Based on Population Pharmacokinetic/Pharmacodynamic Modeling. Alqahtani S; Abouelkheir M; Alsultan A; Elsharawy Y; Alkoraishi A; Osman R; Mansy W Paediatr Drugs; 2018 Jun; 20(3):265-272. PubMed ID: 29569124 [TBL] [Abstract][Full Text] [Related]
6. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Conil JM; Georges B; Breden A; Segonds C; Lavit M; Seguin T; Coley N; Samii K; Chabanon G; Houin G; Saivin S Int J Antimicrob Agents; 2006 Sep; 28(3):226-30. PubMed ID: 16908121 [TBL] [Abstract][Full Text] [Related]
7. Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize Boidin C; Bourguignon L; Cohen S; Roger C; Lefrant JY; Roberts JA; Allaouchiche B; Lepape A; Friggeri A; Goutelle S Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481443 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of Amikacin Pharmacokinetics and Pharmacodynamics for Optimal Initial Dosing Regimen. Kato H; Hagihara M; Hirai J; Sakanashi D; Suematsu H; Nishiyama N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H Drugs R D; 2017 Mar; 17(1):177-187. PubMed ID: 28063020 [TBL] [Abstract][Full Text] [Related]
9. Evaluating amikacin dosage regimens in intensive care unit patients: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. Zazo H; Martín-Suárez A; Lanao JM Int J Antimicrob Agents; 2013 Aug; 42(2):155-60. PubMed ID: 23756322 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn. Yang RH; Rong XZ; Hua R; Zhang T Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586 [TBL] [Abstract][Full Text] [Related]
11. Administration of higher doses of amikacin in early stages of sepsis in critically ill patients. Najmeddin F; Ahmadi A; Mahmoudi L; Sadeghi K; Khalili H; Ahmadvand A; Najafi A; Mojtahedzadeh M Acta Med Iran; 2014; 52(9):703-9. PubMed ID: 25325208 [TBL] [Abstract][Full Text] [Related]
12. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration. Akers KS; Cota JM; Frei CR; Chung KK; Mende K; Murray CK Antimicrob Agents Chemother; 2011 Oct; 55(10):4639-42. PubMed ID: 21825289 [TBL] [Abstract][Full Text] [Related]
13. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719 [TBL] [Abstract][Full Text] [Related]
14. Intravenous Antibiotic and Antifungal Agent Pharmacokinetic-Pharmacodynamic Dosing in Adults with Severe Burn Injury. Cota JM; FakhriRavari A; Rowan MP; Chung KK; Murray CK; Akers KS Clin Ther; 2016 Sep; 38(9):2016-31. PubMed ID: 27586127 [TBL] [Abstract][Full Text] [Related]
15. Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial. De Winter S; Wauters J; Meersseman W; Verhaegen J; Van Wijngaerden E; Peetermans W; Annaert P; Verelst S; Spriet I Int J Antimicrob Agents; 2018 Apr; 51(4):562-570. PubMed ID: 29180278 [TBL] [Abstract][Full Text] [Related]
16. Ceftazidime dosage recommendations in burn patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations. Conil JM; Georges B; Ravat F; Ruiz S; Seguin T; Metsu D; Fourcade O; Saivin S Clin Ther; 2013 Oct; 35(10):1603-12. PubMed ID: 24094465 [TBL] [Abstract][Full Text] [Related]
17. Optimal Amikacin Levels for Patients with Sepsis in Intensive Care Unit of Cipto Mangunkusumo Hospital, Jakarta, Indonesia. Aliska G; Setiabudy R; Purwantyastuti P; Karuniawati A; Sedono R; Dewi TU; Azwar MK Acta Med Indones; 2017 Jul; 49(3):227-235. PubMed ID: 29093233 [TBL] [Abstract][Full Text] [Related]
18. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Lugo G; Castañeda-Hernández G Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600 [TBL] [Abstract][Full Text] [Related]
19. [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis]. Halacová M; Průsa R; Kotaska K; Vávrová V Cas Lek Cesk; 2004; 143(3):187-90. PubMed ID: 15134039 [TBL] [Abstract][Full Text] [Related]
20. Individualised dosing of amikacin in neonates: a pharmacokinetic/pharmacodynamic analysis. Sherwin CM; Svahn S; Van der Linden A; Broadbent RS; Medlicott NJ; Reith DM Eur J Clin Pharmacol; 2009 Jul; 65(7):705-13. PubMed ID: 19305985 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]